Brief: OSE Immunotherapeutics Receives New European Patent Notice Of Allowance For Tedopi®
11/10/2021 06:39
Oct 11 (Reuters) - Ose Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS RECEIVES NEW EUROPEAN PATENT NOTICE
OF
ALLOWANCE FOR TEDOPI®
* NEW PATENT NOTICE OF ALLOWANCE GRANTED IN EUROPE
REINFORCES
PATENT PROTECTION FOR TEDOPI® AND CONFIRMS AN OPTIMIZED
INDUSTRIAL MANUFACTURING PROCESS USING A READY-TO-USE PEPTIDE
EMULSION
* ADDITIONAL PHASE 2 CLINICAL TRIALS ARE ON-GOING TO
CONTINUE
DEVELOPING TEDOPI® IN METASTATIC NSCLC
* THIS PATENT WILL PROVIDE A PROTECTION UNTIL 2038
Source text for Eikon: ID:nBw135TC1a
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO